Joseph Maly
About
Joseph Maly is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology.
According to data from OpenAlex, Joseph Maly has authored 31 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 11 papers in Hematology. Recurrent topics in Joseph Maly's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Joseph Maly is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Joseph Maly collaborates with scholars based in United States, Belgium and Australia. Joseph Maly's co-authors include Hartmut Schneider, Jason P. Kirkness, Thomas Magnuson, Brian M. McGinley, Alison M. Laffan, Alan R. Schwartz, Naresh M. Punjabi, Susheel P. Patil, Philip L. Smith and Michael Schweitzer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Joseph Maly
30 papers receiving 592 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Joseph Maly United States | 11 | 245 | 176 | 169 | 164 | 138 | 31 | 604 | ||
| Cesare Romagnolo Italy | 15 | 22 0.1× | 85 0.5× | 54 0.3× | 65 0.4× | 40 0.3× | 31 | 816 | ||
| Giuseppe Santamaria Italy | 12 | 59 0.2× | 52 0.3× | 16 0.1× | 353 2.2× | 75 0.5× | 24 | 598 | ||
| Alf Zerweck Germany | 4 | 170 0.7× | 47 0.3× | 18 0.1× | 105 0.6× | 17 0.1× | 6 | 447 | ||
| S. Rao Italy | 9 | 34 0.1× | 138 0.8× | 24 0.1× | 126 0.8× | 8 0.1× | 29 | 403 | ||
| Melissa J. Rose United States | 12 | 215 0.9× | 16 0.1× | 30 0.2× | 45 0.3× | 14 0.1× | 30 | 379 | ||
| Claude Chew United States | 8 | 40 0.2× | 210 1.2× | 48 0.3× | 68 0.4× | 6 0.0× | 13 | 653 | ||
| Markus Wirth Germany | 14 | 5 0.0× | 97 0.6× | 199 1.2× | 101 0.6× | 143 1.0× | 59 | 528 | ||
| Derya Aslan Denmark | 11 | 34 0.1× | 56 0.3× | 18 0.1× | 183 1.1× | 8 0.1× | 13 | 354 | ||
| Mi-Woo Lee South Korea | 14 | 14 0.1× | 118 0.7× | 47 0.3× | 38 0.2× | 7 0.1× | 60 | 521 | ||
| Dimitrios Margaritis Greece | 11 | 246 1.0× | 80 0.5× | 55 0.3× | 147 0.9× | 36 | 598 |
Countries citing papers authored by Joseph Maly
Since
Specialization
Citations
This map shows the geographic impact of Joseph Maly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Maly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Maly more than expected).
Fields of papers citing papers by Joseph Maly
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joseph Maly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Maly. The network helps show where Joseph Maly may publish in the future.
Co-authorship network of co-authors of Joseph Maly
This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Maly. A scholar is included among the top collaborators of Joseph Maly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Maly. Joseph Maly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hoffman, James E., Naresh Bumma, Joshua Richter, et al.. (2025). Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial. Clinical Lymphoma Myeloma & Leukemia. 25. S116–S116.
2.
Kelly, William Kevin, Sandy Srinivas, Joseph Maly, et al.. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl).
3.
Fathi, Amir T., Aleksandra Filipović, Dale Schaar, et al.. (2024). A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS. Blood. 144(Supplement 1). 1499–1499.
4.
Khanal, Rashmi, Amitkumar Mehta, Joseph Maly, et al.. (2023). AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.. Journal of Clinical Oncology. 41(16_suppl). 7529–7529.
5.
Lee, Hans C., Naresh Bumma, Joshua Richter, et al.. (2023). LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 41(16_suppl). 8006–8006.
6.
Lee, Hans C., Naresh Bumma, Joshua Richter, et al.. (2023). S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e1610068–e1610068.
7.
Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059.
8.
Khanal, Rashmi, Jennifer N. Saultz, Umar Farooq, et al.. (2022). Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 140(Supplement 1). 12742–12743.
9.
Daver, Naval, Jessica K. Altman, Joseph Maly, et al.. (2020). Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. Blood. 136(Supplement 1). 20–22.
10.
Zhu, Jun, Grzegorz S. Nowakowski, Qingyuan Zhang, et al.. (2019). Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1. Blood. 134(Supplement_1). 5330–5330.
11.
Greenwell, Irl Brian, Ashley D. Staton, Michael J. Lee, et al.. (2018). Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 124(11). 2306–2315.
12.
Maly, Joseph, Beth Christian, Xiaohua Zhu, et al.. (2017). A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 17(6). 347–353.
13.
Greenwell, Irl Brian, Sarah Caulfield, Jeffrey M. Switchenko, et al.. (2017). Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1. Biology of Blood and Marrow Transplantation. 23(3). S265–S266.
14.
Wright, Chadwick, Joseph Maly, Jun Zhang, & Michael V. Knopp. (2016). Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma. PET Clinics. 12(1). 63–82.
15.
Maly, Joseph & James S. Blachly. (2016). Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Current Hematologic Malignancy Reports. 11(1). 52–60.
16.
Calzada, Oscar, Jeffrey M. Switchenko, Joseph Maly, et al.. (2016). Deferred treatment as a viable option for selected patients with mantle cell lymphoma.. Journal of Clinical Oncology. 34(15_suppl). 7567–7567.
17.
Staton, Ashley D., Irl Brian Greenwell, Jeffrey M. Switchenko, et al.. (2016). Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. Blood. 128(22). 1785–1785.
18.
Greenwell, Irl Brian, Ashley D. Staton, Michael J. Lee, et al.. (2016). Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.. Journal of Clinical Oncology. 34(15_suppl). 7565–7565.
19.
Olson, Erin M., Mahmoud Abdel‐Rasoul, Christina Wu, et al.. (2012). Incidence and risk of central nervous system (CNS) metastases as a site of first recurrence in patients (pts) with HER2-positive (HER2+) breast cancer treated with adjuvant trastuzumab (T).. Journal of Clinical Oncology. 30(15_suppl). 609–609.
20.
Kirkness, Jason P., Alan R. Schwartz, Hartmut Schneider, et al.. (2008). Contribution of male sex, age, and obesity to mechanical instability of the upper airway during sleep. Journal of Applied Physiology. 104(6). 1618–1624.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cesare Romagnolo Breakdown of academic impact, for papers by Giuseppe Santamaria Breakdown of academic impact, for papers by Alf Zerweck Breakdown of academic impact, for papers by S. Rao Breakdown of academic impact, for papers by Melissa J. Rose Breakdown of academic impact, for papers by Claude Chew Breakdown of academic impact, for papers by Markus Wirth Breakdown of academic impact, for papers by Derya Aslan Breakdown of academic impact, for papers by Mi-Woo Lee Breakdown of academic impact, for papers by Dimitrios Margaritis